Pfizer and BioNTech launch clinical tria ...
Pfizer and BioNTech announced on October 20 that they have begun Phase 1/2 trials of the mRNA vaccine candidate "BNT162" for the new coronavirus (SARS-CoV-2) in Japan.The study is a randomized, placebo-controlled, observer-blind, phase 1/2 study aimed at assessing the safety, tolerability and immuno... ...